Literature DB >> 12783966

The immunopathogenesis of meningococcal disease.

A J Kvalsvig1, D J Unsworth.   

Abstract

This review describes the mechanisms of the immune response to meningococcal disease, examining the extent to which individual variation of the immune response can determine susceptibility. It concludes by summarising the difficulties encountered by recent efforts to develop new immunomodulatory treatments.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12783966      PMCID： PMC1769980          DOI： 10.1136/jcp.56.6.417

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  119 in total

Review 1.  Neisseria meningitidis: clinical aspects.

Authors:  K A Cartwright; D A Ala'Aldeen
Journal:  J Infect       Date:  1997-01       Impact factor: 6.072

2.  The (alpha2-->8)-linked polysialic acid capsule of group B Neisseria meningitidis modifies multiple steps during interaction with human macrophages.

Authors:  R C Read; S Zimmerli; C Broaddus; D A Sanan; D S Stephens; J D Ernst
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

3.  Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens.

Authors:  F P de Vries; A van Der Ende; J P van Putten; J Dankert
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

4.  Genetic influence on cytokine production and fatal meningococcal disease.

Authors:  R G Westendorp; J A Langermans; T W Huizinga; A H Elouali; C L Verweij; D I Boomsma; J P Vandenbroucke; J P Vandenbrouke
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

5.  Proinflammatory and anti-inflammatory cytokines in meningococcal disease.

Authors:  F A Riordan; O Marzouk; A P Thomson; J A Sills; C A Hart
Journal:  Arch Dis Child       Date:  1996-11       Impact factor: 3.791

6.  Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease.

Authors:  S Nadel; M J Newport; R Booy; M Levin
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

Review 7.  The spleen in children.

Authors:  P A Lane
Journal:  Curr Opin Pediatr       Date:  1995-02       Impact factor: 2.856

8.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

9.  Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992.

Authors:  R M Selik; S Y Chu; J W Ward
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391

10.  Sporadic meningococcal disease in adults: results of a 5-year population-based study.

Authors:  D S Stephens; R A Hajjeh; W S Baughman; R C Harvey; J D Wenger; M M Farley
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391
View more
  8 in total

1.  Prehospital parenteral penicillin for meningitis: Urgent review of treatment criteria is needed.

Authors:  Amanda J Kvalsvig; Michael Baker; Graham Mills
Journal:  BMJ       Date:  2006-06-17

Review 2.  Meningococcal disease and its management in children.

Authors:  C Anthony Hart; Alistair P J Thomson
Journal:  BMJ       Date:  2006-09-30

3.  T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.

Authors:  Karen Robinson; Karl G Wooldridge; Damien B Wells; Amal Hasan; Ian Todd; Adrian Robins; Richard James; Dlawer A A Ala'Aldeen
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Concomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy.

Authors:  Siggeir F Brynjolfsson; Stefania P Bjarnarson; Elena Mori; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

6.  Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design.

Authors:  Namrata Misra; Prasanna Kumar Panda; Kavita Shah; Lala Bihari Sukla; Priyanka Chaubey
Journal:  Bioinformation       Date:  2011-06-23

7.  Fulminant Neisseria meningitidis septicaemia with purpura fulminans requiring limb amputation.

Authors:  H Davies; K Pannu; J Edwards; M Pittman; D Mukherjee
Journal:  IDCases       Date:  2019-11-28

8.  Neisseria meningitidis strains from patients with invasive meningococcal disease differ in stimulation of cytokine production.

Authors:  M Holub; M Scheinostová; O Dzupová; A Fiserová; O Beran; J Kalmusová; M Musilek; P Krízová
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.